REDX
PHARMA PLC
("Redx"
or the "Company")
Redx to Exhibit Three Posters
at AACR Annual Meeting
Poster in collaboration with
Garvan Institute of Medical Research to present pre-clinical data
demonstrating potential of zelasudil in pancreatic ductal
adenocarcinoma
Pre-clinical data highlights
potential of combining zamaporvint with MAPK pathway inhibitors in
gastrointestinal cancer
Presentation of final data
from zamaporvint Phase 1 programme
Alderley Park, UK, 6 March 2024 Redx (AIM:REDX), the clinical-stage biotechnology company
focused on discovering and developing novel, small molecule,
targeted therapeutics for the treatment of fibrotic disease and
cancer today announces that three abstracts submitted by the
Company have been accepted for presentation as posters at the 2024
American Association for Cancer Research (AACR) Annual Meeting in
San Diego, CA, 5 - 10 April 2024.
One poster investigating Redx's lead
asset zelasudil (RXC007), a selective ROCK 2 inhibitor, currently
in Phase 2a development for Idiopathic Pulmonary Fibrosis (IPF)
which has shown promising preclinical efficacy in a range of
models, will be presented in collaboration with the Company's
research partner, the Garvan Institute of Medical Research,
Australia The data from preclinical models of pancreatic cancer
shows the potential of zelasudil to increase survival in mouse
models of pancreatic ductal adenocarcinoma
(PDAC), when used in combination with current standard of
care.
Redx will also present two posters
on zamaporvint (RXC004) a potent and selective porcupine inhibitor
targeting Wnt-ligand dependent cancers, currently in Phase 2
development in hard-to-treat tumors. The first poster highlights
the potential to combine zamaporvint with MAPK pathway inhibitors
in gastrointestinal cancer models showing that co-inhibition of these pathways leads to synergistic effects
in vitro and enhanced
efficacy in vivo. The
second poster, entitled: Final results of the first-in-human study
of the porcupine (PORCN) inhibitor zamaporvint (RXC004) in patients
with advanced solid tumors, will discuss final data from all the
Phase 1 modules of the programme. The abstract from this second
poster will be available on 5 April 2024 at 3:00pm ET.
Richard Armer, Chief Scientific Officer, Redx Pharma
commented: "To have three poster
presentations at a prestigious conference such as AACR is a
testament to the strength of our portfolio. With the potential to
expand the indications for zelasudil beyond IPF and interstitial
lung diseases into fibrotic cancers such as pancreatic; and the
expansion of potential combination treatments with zamaporvint for
hard-to-treat aggressive tumours, we are optimistic about the
utility of our drugs for a number of underserved patient
populations."
Details of the poster
presentations are as follows:
Zelasudil
(RXC007)
Zamaporvint
(RXC004)
1)
2)
|
For
further information, please contact:
|
|
|
|
|
|
|
|
|
|
Redx Pharma Plc
UK
Headquarters
Caitlin Pearson, Head of
Communications
ir@redxpharma.com
|
T: +44 (0)1625 469 918
|
|
|
SPARK Advisory Partners (Nominated Adviser)
|
T: +44 (0)203 368 3550
|
|
|
Matt Davis/ Adam Dawes
|
|
|
|
|
|
|
|
WG
Partners LLP (Joint Broker)
|
T: +44 (0)203 705 9330
|
|
|
Claes Spång/ Satheesh Nadarajah/
David Wilson
|
|
|
|
|
|
|
|
Panmure Gordon (UK) Limited (Joint Broker)
|
T: +44 (0)207 886 2500
|
|
|
Rupert Dearden/ Freddy Crossley/
Emma Earl
|
|
|
|
|
|
|
|
FTI
Consulting
|
T: +44 (0)203 727 1000
|
|
|
Simon Conway/ Ciara
Martin
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
About Redx Pharma Plc
Redx Pharma (AIM: REDX) is a
clinical-stage biotechnology company focused on the discovery and
development of novel, small molecule, targeted therapeutics for the
treatment of fibrotic disease, cancer and the emerging area of
cancer-associated fibrosis. Redx aims to progress its programmes to
clinical proof of concept before evaluating options for further
development and potential value creation. The Company's lead
fibrosis product candidate, the selective ROCK2 inhibitor,
zelasudil (RXC007), is in development for interstitial lung disease
and is undergoing a Phase 2a trial for idiopathic pulmonary
fibrosis (IPF) with topline data expected in H1 2024. The Company's
second fibrosis candidate, RXC008, a
GI-targeted ROCK inhibitor for the treatment of fibrostenotic
Crohn's disease, is in Phase 1 development with healthy volunteer
data expected by the end of 2024. Redx's lead oncology product
candidate, the Porcupine inhibitor zamaporvint (RXC004), being
developed as a targeted treatment for Wnt-ligand dependent cancers,
is expected to report anti-PD-1 combination Phase 2 data during the
first half of 2024, following which Redx will seek a partner for
ongoing development.
The Company has a strong track
record of discovering new drug candidates through its core
strengths in medicinal chemistry and translational science,
enabling the Company to discover and develop differentiated
therapeutics against biologically or clinically validated targets.
The Company's accomplishments are evidenced not only by its
wholly-owned clinical-stage product candidates and discovery
pipeline, but also by its strategic transactions, which includes
the sale of pirtobrutinib (RXC005, LOXO-305), the only non-covalent
or reversible BTK inhibitor now approved by the US FDA, and
transactions with both AstraZeneca and Jazz
Pharmaceuticals.
To subscribe to Email Alerts from
Redx, please visit: www.redxpharma.com/investor-centre/email-alerts/.
